GeoVax Labs, Inc. - Common Stock — Rendiconto Finanziario (NASDAQ:GOVX) | MetaTrader

Apri il grafico completo Full chart

GeoVax Labs, Inc. - Common Stock

GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles in the person being vaccinated.

Notizie

GeoVax Labs, Inc. (GOVX) Discusses Building a Resilient Infectious Disease Preparedness Strategy Focused on Ebola, Marburg, Hantavirus, and Mpox Transcript

All You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to Buy

D. Boral Capital declassa il rating di GeoVax Labs a Hold

D. Boral Capital downgrades GeoVax Labs stock rating to Hold

Why Tilray Brands Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket - Aclarion (NASDAQ:ACON), AXT (NASDAQ:AXTI)

Dow Gains Over 200 Points; Conagra Shares Fall After Q2 Results - Autozi Internet Tech (NASDAQ:AZI), Conagra Brands (NYSE:CAG)

GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript

GeoVax alla Emerging Growth Conference: Promettente vaccino per immunocompromessi

GeoVax at Emerging Growth Conference: Vaccine Promise for Immunocompromised

GeoVax Labs at H.C. Wainwright: Strategic Focus on Vaccine Innovation

GeoVax Labs at Emerging Growth Conference 85: Strategic Vaccine Developments

GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock?